AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Karbon-X Launches SkyXero, a New App for Flight Emissions Tracking as Travelers Seek Trusted Climate Solutions17.4.2026 15:00:00 CEST | Press release
New mobile app enables real-time flight emissions tracking and access to verified climate projects worldwide, launching during Earth Month. CALGARY, AB / ACCESS Newswire / April 17, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced the launch of SkyXero, a new mobile application that enables travelers to measure and balance the emissions of their flights in a few taps. Launching during Earth Month, a period of heightened global focus on environmental impact, SkyXero is now available globally and is designed to meet the growing demand from travelers seeking practical, trusted ways to incorporate climate considerations into their travel decisions. SkyXero allows users to enter flight details, instantly calculate associated emissions, and contribute to a curated portfolio of high-integrity, third-party verified climate projects, including those certi
Karbon-X Launches SkyXero, a New App for Flight Emissions Tracking as Travelers Seek Trusted Climate Solutions17.4.2026 15:00:00 CEST | Press release
New mobile app enables real-time flight emissions tracking and access to verified climate projects worldwide, launching during Earth Month. CALGARY, AB / ACCESS Newswire / April 17, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced the launch of SkyXero, a new mobile application that enables travelers to measure and balance the emissions of their flights in a few taps. Launching during Earth Month, a period of heightened global focus on environmental impact, SkyXero is now available globally and is designed to meet the growing demand from travelers seeking practical, trusted ways to incorporate climate considerations into their travel decisions. SkyXero allows users to enter flight details, instantly calculate associated emissions, and contribute to a curated portfolio of high-integrity, third-party verified climate projects, including those certi
Maxon Announces Free Tools and Mobile Expansion of ZBrush and Cinema 4D16.4.2026 16:55:00 CEST | Press release
Cinema 4D brings professional 3D workflows to iPad. The return of Autograph - now free for individual users. ZBrush expands to Windows on Arm. See it all at NAB 2026. BAD HOMBURG, GERMANY / ACCESS Newswire / April 16, 2026 / Maxon, a leading developer of powerful and intuitive 2D and 3D software and complete graphic design workflows, today announced a major step forward in its mission to make professional creative tools more accessible to artists everywhere. With the debut of Cinema 4D on iPad, the return of the Autograph motion graphics application, and the expansion of Maxon tools to Windows on Arm (WoA) tablet devices, Maxon is lowering the barrier to entry while empowering artists to work where they want, how they want. Visitors to NAB 2026 can see it all at the Maxon booth (N2741). Professional Tools, Broader Access As demand for 3D and motion content accelerates across social media, streaming, gaming, and immersive media, creators are seeking flexible and affordable entry points
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom